Xencor Inc. Stock
Xencor Inc. Stock
A loss of -2.780% shows a downward development for Xencor Inc..
We see a rather positive sentiment for Xencor Inc. with 14 Buy predictions and 2 Sell predictions.
As a result the target price of 22 € shows a very positive potential of 57.14% compared to the current price of 14.0 € for Xencor Inc..
Pros and Cons of Xencor Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Cons
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xencor Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xencor Inc. | -2.780% | -4.762% | 18.644% | -38.053% | -38.596% | -46.154% | -62.567% |
| Ironwood Pharmaceuticals | -1.960% | 2.740% | 10.294% | -9.091% | -28.571% | -73.554% | -70.000% |
| Novocure Ltd | -2.160% | 6.509% | 13.422% | -65.322% | -62.071% | -84.260% | -91.438% |
| Iovance Biotherapeutics Inc. | -2.550% | -7.402% | -14.239% | -75.429% | -73.443% | -71.732% | -95.333% |
Comments
Xencor (NASDAQ:XNCR) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor (NASDAQ:XNCR) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $26.00 price target on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor (NASDAQ:XNCR) had its price target raised by analysts at Royal Bank Of Canada from $18.00 to $19.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
News
Xencor (XNCR) Q2 Revenue Jumps 82%
Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies for serious diseases, reported second quarter 2025 results on August 6, 2025. The company’s GAAP
